Status:
RECRUITING
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Benign Neoplasm
Malignant Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagn...
Detailed Description
If you are present for a preoperative clinic visit the day before your surgery, ICG may be administered via injection. Otherwise, ICG will be administered in the preoperative unit via IV injection at ...
Eligibility Criteria
Inclusion
- All patients 18 years of age or older who present to Massachusetts General Hospital Department of Orthopaedic Surgery with a benign or malignant bone or soft tissue mass that is consented for surgery during the study period.
Exclusion
- Pregnant or nursing patients
- Patients with previously known anaphylaxis to IV contrast or iodine (other allergies may be considered on a case-by-case basis)
- Patients in renal failure who are not cleared for ICG administration by their primary physician or oncologist
Key Trial Info
Start Date :
May 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04752137
Start Date
May 25 2022
End Date
October 1 2026
Last Update
October 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114